After receiving three ketamine therapy sessions in Awakn’s Phase 2 trial, patients with alcohol use disorder achieved an increase in abstinence from around 2% to 86%. This means they abstained from alcohol for an average of 162 of the 180 days following the treatment 👏
The results were so encouraging that the UK government granted the company CA$2.5M to fund Phase 3 of the trial.
The grant covers two-thirds of Awakn’s costs and marks the first time that a Phase 3 psychedelics trial has received government funding.
With 280 patients across 7 sites in the UK, it will be the largest ketamine-assisted therapy trial to date!